Why genomics needs digital health to succeed

Genomics is at a critical inflection point in healthcare, visible through its growing presence in ongoing debates surrounding personal health data and its centrality to precision medicine initiatives around the globe.

Delivering on the promise of genomics depends on three main factors—many of which are within the purview of digital health. We wanted to add some more data to the conversation; we’re excited to announce results from our survey of one thousand consumers and our latest report, The Genomics Inflection Point: Implications for Healthcare.

Note: Only includes US deals >$2M. For the purposes of this report, we did not include basic life sciences tools, synthetic DNA, or gene editing companies



Company Amt Investors Source
Azalea Health $10.5M Kayne Partners, Intersmith Partners MobiHealthNews

Get the full roundup of digital health funding deals since 2011. Subscribe to our funding database.